Condition
Haemophilia A and B With and Without Inhibitors
Locations
Algeria, Bulgaria, Canada, Greece, India, Italy, Japan, Lebanon,
Lithuania, Malaysia, North Macedonia, Poland, Spain, Thailand, Turkey,
United Kingdom, United States
Start date
24/03/2022
Identifiers
Trial ID
NN7415-4616,
NCT number NCT05135559,
Eudract number 2020-000504-11
NCT number NCT05135559,
Eudract number 2020-000504-11
Summary
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.
Participants will have to inject the study medicine every day under the skin with a pen-injector.
The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.
Trial Overview:
Treatment
DRUG: Concizumab
Study type
INTERVENTIONAL
Trial duration
Mar 24 2022 - Nov 02 2029
Participants
90
Phase
III
Are you eligible?
Gender
Male and female
Age
Not Available
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.